8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 19, 2026·SEC
Insmed Incorporated(INSM)Earnings, Financials & Key Ratios
INSM•NASDAQ
$137.09
$29.14B mkt cap·Price updated May 6, 2026
AboutInsmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.Show more
- Revenue$606M+66.7%
- EBITDA-$1.25B-43.8%
- Net Income-$1.28B-39.7%
- EPS (Diluted)-6.42-15.3%
- Gross Margin79.73%+4.3%
- EBITDA Margin-205.59%+13.8%
- Operating Margin-205.59%+14.9%
- Net Margin-210.54%+16.2%
- ROE-249.28%+22.1%
- ROIC-141.82%-54.4%
- Debt/Equity0.06-98.7%
INSM Key Insights
Insmed Incorporated (INSM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 29.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 21.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 36.9x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
INSM Price & Volume
Insmed Incorporated (INSM) stock price & volume — 10-year historical chart
Loading chart...
INSM Growth Metrics
Insmed Incorporated (INSM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years29.83%
3 Years35.2%
TTM30.34%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-36.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-11.53%
Return on Capital
10 Years-53.43%
5 Years-53.11%
3 Years-62.67%
Last Year-70.77%
INSM Recent Earnings
Insmed Incorporated (INSM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 10/12 qtrs (83%)
Q1 2026Latest
Feb 19, 2026EPS
$1.54
Est $1.07
-43.9%
Revenue
$264M
Est $231M
+14.1%
Q4 2025
Oct 30, 2025EPS
$1.75
Est $1.33
-31.6%
Revenue
$142M
Est $115M
+23.3%
Q3 2025
Aug 7, 2025EPS
$1.70
Est $1.30
-30.8%
Revenue
$107M
Est $104M
+3.2%
Q2 2025
May 8, 2025EPS
$1.42
Est $1.34
-6.0%
Revenue
$93M
Est $91M
+1.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $1.54vs $1.07-43.9% | $264Mvs $231M+14.1% |
| Q4 2025 | Oct 30, 2025 | $1.75vs $1.33-31.6% | $142Mvs $115M+23.3% |
| Q3 2025 | Aug 7, 2025 | $1.70vs $1.30-30.8% | $107Mvs $104M+3.2% |
| Q2 2025 | May 8, 2025 | $1.42vs $1.34-6.0% | $93Mvs $91M+1.5% |
Based on last 12 quarters of dataView full earnings history →
INSM Peer Comparison
Insmed Incorporated (INSM) competitors in Commercial Specialty Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 |
Compare INSM vs Peers
Insmed Incorporated (INSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INSM Income Statement
Insmed Incorporated (INSM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 9.84M | 136.47M | 164.41M | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M | 447.02M |
| Revenue Growth % | - | - | 1287.56% | 20.48% | 14.63% | 30.19% | 24.39% | 19.17% | 66.73% | 30.34% |
| Cost of Goods Sold | 2.9M | 2.42M | 24.21M | 39.87M | 44.15M | 55.13M | 65.57M | 85.74M | 122.94M | 134.23M |
| COGS % of Revenue | - | 24.64% | 17.74% | 24.25% | 23.43% | 22.47% | 21.48% | 23.57% | 20.27% | - |
| Gross Profit | -2.9M▲ 0% | 7.41M▲ 355.5% | 112.25M▲ 1414.5% | 124.54M▲ 10.9% | 144.31M▲ 15.9% | 190.23M▲ 31.8% | 239.63M▲ 26.0% | 277.96M▲ 16.0% | 483.49M▲ 73.9% | 312.79M▲ 0% |
| Gross Margin % | - | 75.36% | 82.26% | 75.75% | 76.57% | 77.53% | 78.52% | 76.43% | 79.73% | 69.97% |
| Gross Profit Growth % | -18.99% | 355.5% | 1414.5% | 10.94% | 15.87% | 31.82% | 25.97% | 16% | 73.94% | - |
| Operating Expenses | 188.92M | 314.75M | 347.5M | 389.77M | 519.4M | 647.55M | 949.26M | 1.16B | 1.73B | 1.53B |
| OpEx % of Revenue | - | 3200.31% | 254.64% | 237.07% | 275.6% | 263.92% | 311.02% | 317.9% | 285.32% | - |
| Selling, General & Admin | 79.17M | 168.22M | 210.8M | 203.61M | 234.27M | 265.78M | 344.5M | 461.12M | 701.17M | 631.2M |
| SG&A % of Revenue | - | 1710.4% | 154.47% | 123.84% | 124.31% | 108.33% | 112.87% | 126.78% | 115.62% | - |
| Research & Development | 109.75M | 145.28M | 131.71M | 181.16M | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M | 695.91M |
| R&D % of Revenue | - | 1477.2% | 96.51% | 110.18% | 144.72% | 162.02% | 187.09% | 164.52% | 127.15% | - |
| Other Operating Expenses | 300K | 1.25M | 4.99M | 5M | 12.39M | -15.75M | 33.75M | 96.73M | 257.99M | 2M |
| Operating Income | -188.92M▲ 0% | -307.34M▼ 62.7% | -235.25M▲ 23.5% | -265.23M▼ 12.7% | -375.09M▼ 41.4% | -457.32M▼ 21.9% | -709.63M▼ 55.2% | -878.25M▼ 23.8% | -1.25B▼ 42.0% | -1.22B▲ 0% |
| Operating Margin % | - | -3124.94% | -172.38% | -161.32% | -199.03% | -186.39% | -232.51% | -241.47% | -205.59% | -272.06% |
| Operating Income Growth % | -8.95% | -62.68% | 23.46% | -12.75% | -41.42% | -21.92% | -55.17% | -23.76% | -41.96% | - |
| EBITDA | -186.02M | -302.51M | -225.06M | -251.08M | -360.91M | -446.99M | -699.05M | -867.24M | -1.25B | -1.2B |
| EBITDA Margin % | - | -3075.87% | -164.92% | -152.71% | -191.5% | -182.18% | -229.04% | -238.44% | -205.59% | -269.01% |
| EBITDA Growth % | -8.81% | -62.62% | 25.6% | -11.56% | -43.74% | -23.85% | -56.39% | -24.06% | -43.76% | -47.53% |
| D&A (Non-Cash Add-back) | 2.9M | 4.83M | 10.18M | 14.15M | 14.18M | 10.33M | 10.58M | 11.01M | 0 | 13.63M |
| EBIT | -187M | -300M | -227.25M | -264.52M | -397.83M | -457.7M | -670.76M | -829.81M | 0 | -1.1B |
| Net Interest Income | -4.3M | -15.13M | -17.78M | -27.86M | -40.3M | -15.37M | -39.56M | -31.61M | 0 | -22.07M |
| Interest Income | 1.62M | 10.34M | 9.92M | 1.7M | 174K | 11.08M | 42.13M | 53.31M | 0 | 62.68M |
| Interest Expense | 5.92M | 25.47M | 27.7M | 29.56M | 40.47M | 26.45M | 81.69M | 84.91M | -83.8M | 84.75M |
| Other Income/Expense | -4M | -16.74M | -18.32M | -27.46M | -61.32M | -22.83M | -37.39M | -31.81M | -24.98M | 37.07M |
| Pretax Income | -192.92M▲ 0% | -324.08M▼ 68.0% | -253.56M▲ 21.8% | -292.69M▼ 15.4% | -436.41M▼ 49.1% | -480.15M▼ 10.0% | -747.01M▼ 55.6% | -910.07M▼ 21.8% | -1.27B▼ 39.7% | -1.18B▲ 0% |
| Pretax Margin % | - | -3295.13% | -185.8% | -178.02% | -231.57% | -195.69% | -244.76% | -250.22% | -209.71% | -263.77% |
| Income Tax | -272K | 201K | 777K | 1.4M | -1.76M | 1.38M | 2.56M | 3.71M | 5.03M | 4.74M |
| Effective Tax Rate % | 0.14% | -0.06% | -0.31% | -0.48% | 0.4% | -0.29% | -0.34% | -0.41% | -0.4% | -0.4% |
| Net Income | -192.65M▲ 0% | -324.28M▼ 68.3% | -254.34M▲ 21.6% | -294.09M▼ 15.6% | -434.65M▼ 47.8% | -481.53M▼ 10.8% | -749.57M▼ 55.7% | -913.77M▼ 21.9% | -1.28B▼ 39.7% | -1.18B▲ 0% |
| Net Margin % | - | -3297.17% | -186.37% | -178.87% | -230.63% | -196.26% | -245.59% | -251.24% | -210.54% | -264.83% |
| Net Income Growth % | -9.29% | -68.33% | 21.57% | -15.63% | -47.8% | -10.79% | -55.66% | -21.91% | -39.73% | -36.97% |
| Net Income (Continuing) | -192.65M | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B | -1.18B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.89▲ 0% | -4.22▼ 46.0% | -3.01▲ 28.7% | -3.01▲ 0.0% | -3.88▼ 28.9% | -3.91▼ 0.8% | -5.34▼ 36.6% | -5.57▼ 4.3% | -6.42▼ 15.3% | -5.60▲ 0% |
| EPS Growth % | -1.4% | -46.02% | 28.67% | 0% | -28.9% | -0.77% | -36.57% | -4.31% | -15.26% | -11.53% |
| EPS (Basic) | -2.89 | -4.22 | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 | - |
| Diluted Shares Outstanding | 66.58M | 76.89M | 84.56M | 97.61M | 112.11M | 123.03M | 140.43M | 164.04M | 199.01M | 211.44M |
| Basic Shares Outstanding | 66.58M | 76.84M | 84.56M | 97.61M | 112.11M | 123.03M | 140.43M | 164.04M | 199.01M | 211.76M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INSM Balance Sheet
Insmed Incorporated (INSM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 389.44M | 518.95M | 555.19M | 622.89M | 837.04M | 1.27B | 929.06M | 1.62B | 1.79B | 1.93B |
| Cash & Short-Term Investments | 381.17M | 495.07M | 487.43M | 532.76M | 716.78M | 1.15B | 780.45M | 1.43B | 1.43B | 1.68B |
| Cash Only | 381.17M | 495.07M | 487.43M | 532.76M | 716.78M | 1.07B | 482.37M | 555.03M | 510.44M | 334.76M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 74.24M | 298.07M | 878.8M | 919.6M | 1.35B |
| Accounts Receivable | 0 | 5.51M | 19.23M | 16.56M | 24.35M | 29.71M | 41.19M | 52.01M | 140.86M | 65.26M |
| Days Sales Outstanding | - | 204.67 | 51.44 | 36.77 | 47.16 | 44.2 | 49.26 | 52.2 | 84.78 | 44.92 |
| Inventory | 0 | 7.03M | 28.31M | 49.59M | 67.01M | 69.92M | 83.25M | 98.58M | 132.07M | 120.97M |
| Days Inventory Outstanding | - | 1.06K | 426.82 | 453.98 | 553.96 | 462.97 | 463.38 | 419.64 | 392.11 | 290.85 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 25.47M | 24.18M | 37.24M | 91.24M | 65.6M |
| Total Non-Current Assets | 72.6M | 85.61M | 187.1M | 173.26M | 406.47M | 383.05M | 400.77M | 403.57M | 470.35M | 428.93M |
| Property, Plant & Equipment | 12.43M | 22.64M | 113.11M | 97.23M | 95.52M | 102.08M | 104.39M | 115.58M | 139.21M | 116.62M |
| Fixed Asset Turnover | - | 0.43x | 1.21x | 1.69x | 1.97x | 2.40x | 2.92x | 3.15x | 4.36x | 3.84x |
| Goodwill | 0 | 0 | 0 | 0 | 136.11M | 136.11M | 136.11M | 136.11M | 136.11M | 136.11M |
| Intangible Assets | 58.2M | 58.67M | 53.68M | 49.26M | 73.81M | 68.76M | 63.7M | 58.65M | 97.65M | 84.59M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 50.04M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.97M | 4.3M | 20.31M | 26.77M | 50.99M | 76.1M | 96.57M | 93.23M | 97.38M | 363.41M |
| Total Assets | 462.05M▲ 0% | 604.56M▲ 30.8% | 742.3M▲ 22.8% | 796.15M▲ 7.3% | 1.24B▲ 56.2% | 1.66B▲ 33.2% | 1.33B▼ 19.7% | 2.03B▲ 52.3% | 2.26B▲ 11.8% | 2.36B▲ 0% |
| Asset Turnover | - | 0.02x | 0.18x | 0.21x | 0.15x | 0.15x | 0.23x | 0.18x | 0.27x | 0.21x |
| Asset Growth % | 94.17% | 30.84% | 22.78% | 7.26% | 56.19% | 33.21% | -19.72% | 52.29% | 11.82% | 159.81% |
| Total Current Liabilities | 44.66M | 79.73M | 85.24M | 118.81M | 135.17M | 190.24M | 225.63M | 297.53M | 468.87M | 417.21M |
| Accounts Payable | 14.67M | 17.74M | 13.18M | 42.85M | 35.78M | 50.46M | 65.39M | 73.03M | 0 | 79.59M |
| Days Payables Outstanding | 1.85K | 2.67K | 198.75 | 392.29 | 295.82 | 334.11 | 364 | 310.9 | - | 193.3 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.5M | 12.81M | 12.32M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 12.84M | 23.74M | 19.42M | 25.59M | 33.46M | 42.74M | 55.63M | 127.69M | 456.06M | 325.3M |
| Current Ratio | 8.72x | 6.51x | 6.51x | 5.24x | 6.19x | 6.69x | 4.12x | 5.45x | 3.83x | 3.83x |
| Quick Ratio | 8.72x | 6.42x | 6.18x | 4.83x | 5.70x | 6.33x | 3.75x | 5.12x | 3.54x | 3.54x |
| Cash Conversion Cycle | - | -1.41K | 279.51 | 98.46 | 305.3 | 173.06 | 148.64 | 160.94 | - | 142.47 |
| Total Non-Current Liabilities | 56.33M | 316.56M | 395.38M | 401.46M | 697.87M | 1.38B | 1.44B | 1.44B | 1.06B | 997.95M |
| Long-Term Debt | 55.57M | 316.56M | 335.94M | 356.32M | 566.59M | 1.13B | 1.16B | 1.26B | 32.89M | 703.57M |
| Capital Lease Obligations | 0 | 0 | 48.84M | 35.97M | 35.54M | 44.49M | 38.04M | 33.18M | 0 | 124.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 765K | 0 | 10.61M | 9.18M | 95.74M | 208.5M | 242.78M | 144.7M | 1.02B | 760.98M |
| Total Liabilities | 100.99M | 396.29M | 480.63M | 520.27M | 833.04M | 1.57B | 1.66B | 1.74B | 1.53B | 1.42B |
| Total Debt | 55.57M | 316.56M | 397.04M | 404.84M | 612.27M | 1.18B | 1.2B | 1.31B | 45.71M | 745.08M |
| Net Debt | -325.6M | -178.51M | -90.39M | -127.91M | -104.51M | 103.83M | 721.62M | 759.09M | -464.74M | 410.31M |
| Debt / Equity | 0.15x | 1.52x | 1.52x | 1.47x | 1.49x | 13.39x | - | 4.60x | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.62x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.34x |
| Interest Coverage | -31.89x | -12.07x | -8.49x | -8.97x | -9.27x | -17.29x | -8.69x | -10.34x | - | -12.98x |
| Total Equity | 361.06M▲ 0% | 208.27M▼ 42.3% | 261.67M▲ 25.6% | 275.88M▲ 5.4% | 410.47M▲ 48.8% | 87.95M▼ 78.6% | -331.92M▼ 477.4% | 285.38M▲ 186.0% | 738.98M▲ 158.9% | 945.57M▲ 0% |
| Equity Growth % | 133.72% | -42.32% | 25.64% | 5.43% | 48.78% | -78.57% | -477.4% | 185.98% | 158.95% | 3522.39% |
| Book Value per Share | 5.42 | 2.71 | 3.09 | 2.83 | 3.66 | 0.71 | -2.36 | 1.74 | 3.71 | 4.47 |
| Total Shareholders' Equity | 361.06M | 208.27M | 261.67M | 275.88M | 410.47M | 87.95M | -331.92M | 285.38M | 738.98M | 945.57M |
| Common Stock | 766K | 773K | 897K | 1.03M | 1.19M | 1.36M | 1.48M | 1.79M | 2.14M | 2.13M |
| Retained Earnings | -957.88M | -1.28B | -1.54B | -1.83B | -2.27B | -2.7B | -3.45B | -4.36B | -5.64B | -5.31B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3K | -9K | -10K | 193K | 968K | 756K | -745K | -2.29M | 1.46M | 2M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INSM Cash Flow Statement
Insmed Incorporated (INSM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -159.62M | -257.98M | -250.65M | -219.35M | -363.3M | -400.44M | -536.25M | -683.88M | -935.01M | -935.01M |
| Operating CF Margin % | - | -2623.05% | -183.67% | -133.41% | -192.77% | -163.21% | -175.7% | -188.03% | -154.19% | - |
| Operating CF Growth % | -8.8% | -61.62% | 2.84% | 12.49% | -65.63% | -10.22% | -33.91% | -27.53% | -36.72% | -180.89% |
| Net Income | -192.65M | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B | -1.18B |
| Depreciation & Amortization | 2.9M | 4.83M | 10.18M | 14.15M | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M | 13.63M |
| Stock-Based Compensation | 18.07M | 26.24M | 26.97M | 36.16M | 46.02M | 57.69M | 74.78M | 96.83M | 152.71M | 140.22M |
| Deferred Taxes | 0 | 2.21M | 0 | 0 | 17.69M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 776K | 17.29M | 29.5M | 27.39M | 52.04M | 6.5M | 167.18M | 125.22M | 172.6M | 161.12M |
| Working Capital Changes | 11.28M | 15.74M | -62.97M | -2.95M | -58.58M | 6.58M | -39.22M | -3.18M | 0 | -14.53M |
| Change in Receivables | 0 | -5.51M | -13.72M | 2.67M | -8.12M | -6.42M | -11.96M | -12.93M | -88.31M | -22.82M |
| Change in Inventory | 0 | -7.03M | -21.28M | -21.18M | -17.46M | -1.71M | -13.61M | -17.04M | -31.52M | -21.88M |
| Change in Payables | 3.6M | 3.87M | -4.97M | 29.82M | -7.58M | 50.01M | 15.15M | 44.59M | 100.07M | 50.86M |
| Cash from Investing | -3M | -14.81M | -42.27M | -6.82M | -64.28M | -34.58M | -223.6M | -583.17M | -64.58M | -322.23M |
| Capital Expenditures | -3M | -14.81M | -42.27M | -6.82M | -7.29M | -9.88M | -13.29M | -21.92M | -32.56M | -22.74M |
| CapEx % of Revenue | - | 150.63% | 30.97% | 4.15% | 3.87% | 4.03% | 4.35% | 6.03% | 5.37% | - |
| Acquisitions | 0 | 0 | 0 | 0 | -6.7M | 24.71M | 3.42M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -57M | -24.71M | 0 | 0 | -30M | 0 |
| Cash from Financing | 381.09M | 386.74M | 285.28M | 271M | 612.55M | 793.27M | 168.44M | 1.34B | 954.07M | 1.08B |
| Debt Issued (Net) | 0 | 392.17M | 0 | 769K | 336.34M | 349.4M | -1.22M | 147.39M | 0 | 141.43M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3.43M | -14.24M | 24.2M | 25.14M | 6.32M | 151.72M | 17.18M | 109.51M | 954.07M | 0 |
| Net Change in Cash | 218.57M▲ 0% | 113.91M▼ 47.9% | -7.64M▼ 106.7% | 45.33M▲ 693.1% | 184.03M▲ 306.0% | 357.25M▲ 94.1% | -591.66M▼ 265.6% | 72.66M▲ 112.3% | -44.59M▼ 161.4% | -126.69M▲ 0% |
| Free Cash Flow | -162.62M▲ 0% | -272.79M▼ 67.7% | -292.92M▼ 7.4% | -226.17M▲ 22.8% | -370.59M▼ 63.9% | -410.32M▼ 10.7% | -549.53M▼ 33.9% | -705.8M▼ 28.4% | -967.58M▼ 37.1% | -906.14M▲ 0% |
| FCF Margin % | - | -2773.68% | -214.64% | -137.56% | -196.64% | -167.23% | -180.05% | -194.06% | -159.55% | -202.71% |
| FCF Growth % | -7.76% | -67.75% | -7.38% | 22.79% | -63.86% | -10.72% | -33.93% | -28.44% | -37.09% | -42.47% |
| FCF per Share | -2.44 | -3.55 | -3.46 | -2.32 | -3.31 | -3.33 | -3.91 | -4.30 | -4.86 | -4.86 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.80x | 0.99x | 0.75x | 0.84x | 0.83x | 0.72x | 0.75x | 0.73x | 0.77x |
| Interest Paid | 5.17M | 6.29M | 7.88M | 9.19M | 10.89M | 10.16M | 35.79M | 40.57M | 0 | 41.63M |
| Taxes Paid | 166K | 154K | 339K | 814K | 1.56M | 1.72M | 1.96M | 2.5M | 0 | 602K |
INSM Key Ratios
Insmed Incorporated (INSM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -74.74% | -113.92% | -108.24% | -109.42% | -126.66% | -193.22% | - | -320.2% | -249.28% | -125.2% |
| Return on Invested Capital (ROIC) | -344.98% | -706.93% | -175.53% | -124.62% | -123.95% | -137.82% | -183.06% | -91.86% | -141.82% | -141.82% |
| Gross Margin | - | 75.36% | 82.26% | 75.75% | 76.57% | 77.53% | 78.52% | 76.43% | 79.73% | 69.97% |
| Net Margin | - | -3297.17% | -186.37% | -178.87% | -230.63% | -196.26% | -245.59% | -251.24% | -210.54% | -264.83% |
| Debt / Equity | 0.15x | 1.52x | 1.52x | 1.47x | 1.49x | 13.39x | - | 4.60x | 0.06x | 0.06x |
| Interest Coverage | -31.89x | -12.07x | -8.49x | -8.97x | -9.27x | -17.29x | -8.69x | -10.34x | - | -12.98x |
| FCF Conversion | 0.83x | 0.80x | 0.99x | 0.75x | 0.84x | 0.83x | 0.72x | 0.75x | 0.73x | 0.77x |
| Revenue Growth | - | - | 1287.56% | 20.48% | 14.63% | 30.19% | 24.39% | 19.17% | 66.73% | 30.34% |
INSM SEC Filings & Documents
Insmed Incorporated (INSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
INSM Frequently Asked Questions
Insmed Incorporated (INSM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Insmed Incorporated (INSM) reported $447.0M in revenue for fiscal year 2025. This represents a 44702100% increase from $0.0M in 1999.
Insmed Incorporated (INSM) grew revenue by 66.7% over the past year. This is strong growth.
Insmed Incorporated (INSM) reported a net loss of $1.18B for fiscal year 2025.
Dividend & Returns
Insmed Incorporated (INSM) has a return on equity (ROE) of -249.3%. Negative ROE indicates the company is unprofitable.
Insmed Incorporated (INSM) had negative free cash flow of $906.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More INSM
Insmed Incorporated (INSM) financial analysis — history, returns, DCA and operating performance tools
Full INSM Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates